NCT04297709 (SUPERB-CF) is a clinical trial in Cystic Fibrosis, sponsored by Mologic Ltd.

Who is sponsoring NCT04297709?

NCT04297709 is sponsored by Mologic Ltd.

What condition does NCT04297709 study?

NCT04297709 studies Cystic Fibrosis.

Is NCT04297709 still recruiting?

NCT04297709 is currently completed. Last updated 11 March 2020.

Last reviewed 2020-03-11 · How we verify

NCT04297709: SUPERB-CF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Urinary Predictors of Exacerbations by Biomarkers in Cystic Fibrosis

Completed Last updated 11 March 2020

What this trial tests

trial in Cystic Fibrosis in 29 participants. Completed in 31 July 2019.

Timeline

1 February 2018

Primary endpoint
31 July 2019

31 July 2019

Quick facts

Lead sponsor	Mologic Ltd
Status	Completed
Study type	OBSERVATIONAL
Enrollment	29
Start date	1 February 2018
Primary completion	31 July 2019
Estimated completion	31 July 2019
Sites	1 location across United Kingdom

Conditions studied

Cystic Fibrosis — all drugs for Cystic Fibrosis →

Sponsor

Mologic Ltd

Who can join

18 and older, any sex, with Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study of Urinary Predictors of Exacerbations by Biomarkers in Cystic Fibrosis

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting

Other Mologic Ltd trials

Trials by the same sponsor.

NCT04296318 — COPD Exacerbation Alert System With urinE anaLysis Using the HEADSTART Device · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04297709 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mologic Ltd
Last refreshed: 11 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04297709.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing